Perry Sternberg
Net worth: - $ as of 30/05/2026
Net worth: - $ as of 30/05/2026
Perry J.
Sternberg is Chief Executive Officer & Director at Sydnexis, Inc. since 2024.
Mr. Sternberg is Lead Independent Director at Harrow, Inc. since 2022.
Mr. Sternberg is Director at Surface Ophthalmics, Inc. Formerly, Mr. Sternberg was President & Chief Executive Officer at Corium LLC (Massachusetts) from 2019 to 2024.
Mr. Sternberg was Chief Executive Officer at Corium Innovations, Inc. Mr. Sternberg was President, Chief Executive Officer & Director at Corium LLC.
Mr. Sternberg was Head-Neuroscience Business Unit at Shire Plc from 2013 to 2019.
Mr. Sternberg was Vice President & General Manager at Bausch & Lomb, Inc. Mr. Sternberg completed undergraduate studies at The Pennsylvania State University in 1990.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HARROW, INC. -.--% | 17/06/2026 | 0 ( -.--% ) | - $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| HARROW, INC. | Director/Board Member | 30/03/2022 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on development and commercialization of therapeutics | Director/Board Member | - |
Sydnexis, Inc.
Sydnexis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Chief Executive Officer | 04/08/2024 |
| Companies | Position | End |
|---|---|---|
| CORIUM INTERNATIONAL INC | Chief Executive Officer | 30/06/2024 |
Corium Pharma Solutions, Inc.
Corium Pharma Solutions, Inc. Medical SpecialtiesHealth Technology Operates as a biopharmaceutical contract development and manufacturing organization that develops transdermal patches & oral thin-film systems | Chief Executive Officer | 16/01/2023 |
| SHIRE | Corporate Officer/Principal | 31/12/2018 |
Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business/
Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business/ Medical SpecialtiesHealth Technology Manufactures and markets hearing aids and related products | Corporate Officer/Principal | - |
Corium LLC
Corium LLC BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel neuroscience therapies | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business/
Bausch & Lomb, Inc. /Miracle-Ear Hearing Aid Business/ Medical SpecialtiesHealth Technology Manufactures and markets hearing aids and related products | Health Technology |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corium International, Inc.
Corium International, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of novel neuroscience therapies | Health Technology |
Harrow, Inc.
Harrow, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development, production, and sale of innovative medications | Health Technology |
Sydnexis, Inc.
Sydnexis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on development and commercialization of therapeutics | Health Technology |
Corium Pharma Solutions, Inc.
Corium Pharma Solutions, Inc. Medical SpecialtiesHealth Technology Operates as a biopharmaceutical contract development and manufacturing organization that develops transdermal patches & oral thin-film systems | Health Technology |
Corium LLC
Corium LLC BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel neuroscience therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions